The CMD on 17 November clarified the long-term investment case by providing a clearer organic growth framework. Moreover, a lean cost structure and execution speed will remain the company's core competitive advantages. Capital discipline also means that Incap will not buy revenue growth at the valuation multiples currently being seen in the EMS markets. The new financial targets indicate 11% average organic growth for 2027-29. However, adjusted EBITA growth could remain below revenue growth in the medium term, we believe. Overall, the financial targets, combined with reduced earnings volatility and capital discipline, could potentially reduce the valuation discount to peers. Incap's 2026E P/E and EV/EBIT combined are ~24% below the peer group median. Our fair value range remains at EUR 10.6-12.9, based on our DCF analysis, backed by a peer group comparison.
LÄS MER